Liposomal Bupivacaine Plus Bupivacaine Versus Ropivacaine Plus Dexamethasone Brachial Plexus Blockade for Arthroscopic Rotator Cuff Repair: An Unblinded Randomized Controlled Trial.

Brachial plexus blockade is utilized for pain control during arthroscopic rotator cuff repair. The purpose of the present study was to evaluate brachial plexus blockade with liposomal bupivacaine plus bupivacaine (LB+B) as compared with ropivacaine plus dexamethasone (R+D) for arthroscopic rotator cuff repair. Our hypothesis was that the use of LB+B would result in lower pain scores and opioid consumption as compared with R+D. Methods: We performed a randomized controlled trial of 45 patients receiving ultrasound-guided brachial plexus blockade with LB+B and 44 patients receiving R+D prior to arthroscopic rotator cuff repair. The "worst pain" score in a 24-hour period, oral morphine equivalent dose (OMED), and overall benefit of analgesia score (OBAS) were recorded for 8 days following surgery. Results: Patient-reported "worst pain" was significantly lower in the LB+B group as compared with the R+D group on postoperative day 0 through day 5. OMED was significantly less for all 8 days studied, with an average cumulative 8-day OMED of 48.5 milligram equivalents in the LB+B group as compared with 190.1 milligram equivalents in the R+D group (p < 0.001). The OBAS score was significantly lower in the LB+B group as compared with R+D group on all postoperative days. The use of LB+B for brachial plexus blockade resulted in a 4% complication rate in a population of patients predominantly with American Society of Anesthesiologists (ASA) scores of 1 and 2. Conclusions: The use of LB+B for brachial plexus blockade during arthroscopic rotator cuff repair was associated with a significant and sustained decrease in the "worst pain" score, opioid consumption, and OBAS compared with R+D. LB+B for brachial plexus blockade also exhibited a strong safety profile. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

Examining Facets of Mindfulness in the Relationship Between Invalidating Childhood Environments and Emotion Regulation.

Research has shown that growing up in an environment in which emotions are invalidated (i.e., ignored or responded to negatively) by parents is associated with later difficulties regulating emotions. Meanwhile, dispositional mindfulness has been shown to engender a greater capacity for emotion regulation, through use of adaptive strategies like cognitive reframing and minimizing use of maladaptive strategies like expressive suppression. The current study aimed to explore the role of invalidating childhood environments on use of cognitive reappraisal and expressive suppression as emotion regulation skills and to investigate the role of mindfulness in this relationship. Participants were recruited via Amazon Mechanical Turk (n = 1094, Mage = 58.3% women) and completed self-report measures assessing perceptions of maternal invalidation, mindfulness, and emotion regulation. Results demonstrated that the mindfulness facets of describing, non-judging, and non-reactivity partially mediated the relationship between perception of maternal invalidation and expressive suppression. Awareness and non-reactivity were found to mediate the relationship between perception of maternal invalidation and cognitive reappraisal. Clinical implications are discussed.

The Chicago Asthma Consortium: a community coalition targeting reductions in asthma morbidity.

The problem of asthma in Chicago remains a complex one, and it is too early to know whether any programs and efforts have had a discernible effect, but the Chicago Asthma Consortium continues to expand its membership and to define its mission. The successes have come from harnessing the passion of the individual members to move the projects forward. As the focus of the consortium moves to addressing system-wide problems in asthma care and the delivery of that care, the consortium is undertaking the construction of a guide for future efforts. In this way, the consortium will fulfill its vision of creating a comprehensive, community-wide plan for the management of asthma, impacting on the unacceptable current levels of morbidity and mortality of the disease.